Investigating BET inhibitors for treating solitary fibrous tumors
Official title: Bromodomain and extra-terminal motif (BET) inhibitors in Solitary fibrous tumor (SFT)
Funded at University of Texas Dallas · NIH-11056128 · Data updated 2026-11-12
This study is looking at a type of tumor called solitary fibrous tumors (SFTs) and testing a new treatment using special drugs to see if they can help shrink these tumors, while also learning more about the genes that make them grow, so we can find better ways to help patients like you.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Texas Dallas NIH-funded |
| Lab location | 1 site (Richardson, United States) |
| Project start | April 1, 2024 |
| Project end | March 31, 2029 |
| Funding year | 2025 |
| Award (this year) | $502,291 |
| NIH project number | 5R01CA283330-02 |
| Project ID | NIH-11056128 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are adults diagnosed with solitary fibrous tumors, particularly those who have not responded to existing treatments.
✕Less likely to help
Patients with solitary fibrous tumors who are not eligible for experimental treatments or those with other concurrent severe health conditions may not benefit from this research.
What this research studies
This research focuses on solitary fibrous tumors (SFTs), a type of soft-tissue sarcoma that can occur in various locations, particularly in the meninges of the head. The study aims to explore the effectiveness of bromodomain and extra-terminal motif (BET) inhibitors in treating SFTs, which currently lack an approved chemotherapy regimen. By utilizing CRISPR-based genome editing, the research seeks to understand the genetic factors contributing to tumor growth and to develop targeted therapies that could improve patient outcomes. Patients may be monitored for tumor response to these novel treatments over the course of the study.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatment options for patients with solitary fibrous tumors, potentially improving survival rates and quality of life.
How similar studies have gone: While anti-angiogenic drugs have shown limited success in treating SFTs, this approach using BET inhibitors is relatively novel and has not been extensively tested in this context.
Where this research is happening
-
University of Texas Dallas
Richardson, United States Active
Researchers
- Principal investigator: Bleris, Leonidas — University of Texas Dallas
- Study coordinator: Bleris, Leonidas
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.